Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2019-10-16

Original market date: See footnote 1

2019-10-16

Product name:

MINT-ONDANSETRON ODT

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02487349

Product Monograph/Veterinary Labelling:

Date: 2020-12-31 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

MINT PHARMACEUTICALS INC
6575 Davand Drive
Mississauga
Ontario
Canada  L5T 2M3

Class: 

Human

Dosage form(s):

Tablet (Orally Disintegrating)

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

56:22.20   5-HT3 RECEPTOR ANTAGONISTS

Anatomical Therapeutic Chemical (ATC): See footnote 4

A04AA01  ONDANSETRON

Active ingredient group (AIG) number:See footnote 5

0131120001

List of active ingredient(s)
Active ingredient(s) Strength
ONDANSETRON 8 MG

Application information

Related information

Contact us

Version 3.8.0
Date modified: